SEC Form 4 · accession 0001209191-15-019227
BELLICUM PHARMACEUTICALS, INC · BLCM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ken Moseley
Officer — Vice President
Period of report
Feb 24, 2015
Accepted (ET)
Feb 26, 2015 · 6:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001358403
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $23.47 | Feb 24, 2015 | A | 60,000 | A | — | Feb 23, 2025 | Common Stock | 60,000 | 60,000 | D |
Explanation of responses
- F125% of the shares subject to the stock option vest and become exercisable on February 24, 2016, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.